Experimental virus therapy for brain cancer trial pulled before it began
NCT ID NCT04105374
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study planned to test a two-part experimental treatment for newly diagnosed glioblastoma, a fast-growing brain cancer. The treatment combined a modified virus (Toca 511) designed to enter tumor cells and an extended-release antifungal drug (Toca FC) that the virus helps turn into a cancer-killing agent. This was to be added to standard therapy (chemotherapy and radiation). However, the trial was withdrawn before any patients were enrolled, so no data were collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Toca 511 (a modified virus) and Toca FC (an extended-release antifungal drug)
What this could lead to
If it had worked, this approach could have helped shrink or stabilize glioblastoma tumors and possibly extend patients' lives.
What could go wrong
The trial was withdrawn before enrolling any participants, so no results are available. Early-phase studies of similar approaches have shown mixed outcomes, and the treatment carries risks from the virus and chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.